OncoTherapy Science Inc (30O)

Currency in EUR
0.1400
-0.0540(-27.84%)
Delayed Data·
30O Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
30O is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.14000.1400
52 wk Range
0.09100.3200
Key Statistics
Bid/Ask
0.145 / 0.195
Prev. Close
0.194
Open
0.14
Day's Range
0.14-0.14
52 wk Range
0.091-0.32
Volume
-
Average Volume (3m)
161
1-Year Change
-40.49%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
30O Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

OncoTherapy Science Inc Company Profile

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.

Compare 30O to Peers and Sector

Metrics to compare
30O
Peers
Sector
Relationship
P/E Ratio
−9.9x−5.4x−0.5x
PEG Ratio
−0.200.000.00
Price/Book
11.1x4.2x2.6x
Price / LTM Sales
10.7x48.8x3.3x
Upside (Analyst Target)
-66.0%43.5%
Fair Value Upside
Unlock19.0%6.3%Unlock

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.36 / --
Revenue / Forecast
187.00M / --
EPS Revisions
Last 90 days

30O Income Statement

FAQ

What Stock Exchange Does OncoTherapy Science Inc Trade On?

OncoTherapy Science Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for OncoTherapy Science Inc?

The stock symbol for OncoTherapy Science Inc is "30O."

What Is the OncoTherapy Science Inc Market Cap?

As of today, OncoTherapy Science Inc market cap is 45.73M.

What Is OncoTherapy Science Inc's Earnings Per Share (TTM)?

The OncoTherapy Science Inc EPS (TTM) is -3.12.

From a Technical Analysis Perspective, Is 30O a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has OncoTherapy Science Inc Stock Split?

OncoTherapy Science Inc has split 0 times.

How Many Employees Does OncoTherapy Science Inc Have?

OncoTherapy Science Inc has 47 employees.

What is the current trading status of OncoTherapy Science Inc (30O)?

As of 05 Aug 2025, OncoTherapy Science Inc (30O) is trading at a price of 0.14, with a previous close of 0.19. The stock has fluctuated within a day range of 0.14 to 0.14, while its 52-week range spans from 0.09 to 0.32.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.